Assessment of cytotoxicity induced by novel pMHC bi-specific antibodies in vitro (Old ID 27757)

Myrio Therapeutics Pty Ltd
Hillary Vanderven
Role

Principal Investigator

Description

Optimisation and performance of in vitro cell-binding and cytotoxicity assays to assess the capacity of novel bi-specific peptide-MHC (pMHC) antibodies to bind and/or cause killing of peptide-pulsed and influenza-infected cells in vitro.

Date

14 Jul 2022 - 25 Jul 2023

Project Type

CONTRACT_RESEARCH

Keywords

Antibody-based therapies;Influenza virus

Funding Body

Myrio Therapeutics Pty Ltd

Amount

11376

Project Team

N/A